Needham & Company Reiterates Buy on Skyworks Solutions (SWKS) Following 3Q Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Drexel Hamilton Reiterates Buy on Skyworks Solutions (SWKS) Following Solid 3Q
July 22, 2016 6:56 AM EDTDrexel Hamilton reiterated a Buy rating and $90.00 price target on Skyworks Solutions (NASDAQ: SWKS) following the company's 3Q earnings report. Revenue beat Street expectations by about $1.5 million, and the company is guiding to September sales growth of 10-11%, with a mid-point that is... More
After-Hours Stock Movers 07/21 (PBYI) (EYES) (PFPT) Higher; (SKX) (ATHN) (P) Lower (more...)
July 21, 2016 5:59 PM EDTToday's After-Hours Movers
Puma Biotechnology, Inc. (NYSE: PBYI) 18.8% HIGHER; submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead product candidate PB272 (neratinib) for the extended adjuvant treatment of patients with early stage HER2-overexpressed/amplified breast cancer who have received prior adjuvant trastuzumab (Herceptin®)-based therapy. Also, announced updated results from the Phase III clinical trial of Pumas investigational drug PB272 (neratinib) for the extended adjuvant treatment of HER2-positive early stage breast cancer (ExteNET trial). The ExteNET trial is a... More
Skyworks Solutions (SWKS) Raises Quarterly Dividend 7.7% to $0.28 and Approves $400M Buyback
July 21, 2016 4:22 PM EDTSkyworks Solutions (NASDAQ: SWKS) declared a quarterly dividend of $0.28 per share, or $1.12 annualized. This is a 7.7% increase from the prior dividend of $0.26.
The dividend will be payable on August 25, 2016, to stockholders of record on July 21, 2016, with an ex-dividend date of July 19, 2016.
The annual yield on the dividend is 1.6 percent.
In addition,... More
Skyworks Solutions (SWKS) Tops Q3 EPS by 3c; Guides Q4 In-Line
July 21, 2016 4:17 PM EDTSkyworks Solutions (NASDAQ: SWKS) reported Q3 EPS of $1.24, $0.03 better than the analyst estimate of $1.21. Revenue for the quarter came in at $751.7 million versus the consensus estimate of $750.22 million.
GUIDANCE:
Skyworks Solutions sees Q4 2016 EPS of $1.43, versus the consensus of $1.42. Skyworks... More
Trading Radar for 7/21: GM (GM), Chipotle (CMG), AMD (AMD), Starbucks (SBUX), Pandora (P), Visa (V), Travelers (TRV) Report
July 20, 2016 2:39 PM EDTThe Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Economics:
8:30am EDT
9:00am EDT
FHFA Housing Price Index - no Street consensusEarnings:
ABB Ltd. (NYSE: ABB) - consensus EPS $0.26
Adeptus Health (NYSE: ADPT) - consensus EPS $0.51
Alaska Air Group (NYSE: ALK) - consensus EPS $2.07... More

